<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2009</study_start_year><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2073140</full_dataset_link><location>United States</location><study_start_month>5</study_start_month><keyword>Measurable Colorectal Cancer</keyword><keyword>Stratified by MSI Status</keyword><keyword>Olaparib</keyword><keyword>Stage IV</keyword><keyword>MSI status</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status</name><description>This study is being carried out to see if the new drug, olaparib (AZD2281), can effectively and safely treat advanced large bowel cancer. The primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient’s cancer by causing a response and increasing the time it takes for the cancer to progress.</description><dates><creation>2009-05-15</creation></dates><accession>2073140</accession><cross_references><ClinicalTrials___gov>NCT00912743</ClinicalTrials___gov></cross_references></HashMap>